摘要:
The present invention relates to an electronic device comprising a compound according to formula 1 A-B (1) and wherein - Ar 1 is a C6-C18 arylene, which can be monocyclic or polycyclic and may be optionally substituted by one or more C 1 -C 10 -alkyl or C 3 -C 10 -cycloalkyl groups, - Ar 2 is a C6-C18 arene skeleton, optionally substituted with electron donating groups R 4 , - B 1 and B 2 are independently selected from B and Ar 2 , - B 3 is independently selected from the same group as B - R 1 , R 2 , R 3 are independently selected from alkyl, arylalkyl, cycloalkyl, aryl, dialkylamino, - x is selected from 0, 1, 2 and 3, wherein for x > 1 each Ar 1 may be different, - y is a non-zero integer up to the overall count of valence sites on the arene skeleton, - z is a integer from zero up to the overall count of valence sites on the arene skeleton minus y; as well as a respective compound according to formula A-B
摘要:
or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
摘要:
The present invention provides new metal complexes which can be advantageously used for homo- or copolymerization of at least one diene monomer optionally in the presence of one or more copolymerisable comonomers and which in particular provide cis-polydienes starting from conjugated dienes.
摘要:
Tb(TMHD)3OPNP where TMHD is 2,2,6,6-tetramethyl-3,5-heptanedionato and OPNP is diphenylphosphonimide triphenyl phosphorane is an electroluminescent material which emits white light at an applied voltage of above 12 volts.
摘要:
A process for synthesizing an optically active starting material, represented by general formula (I), for various medicines with a high optical purity in a good yield, wherein R1 represents hydrogen or hydroxyl-protecting group: * represents an asymmetric carbon atom; R2' represents hydrogen or optionally substituted lower alkyl; and Q represents -C=P(Ph)¿3?, -CH2P(O)(OMe)2 or -CH2S(O)Me. More particularly, an intermediate for the synthesis of an optically active compound useful for inhibiting the activity of HMG-CoA reductase to thereby inhibit the biosynthesis of cholesterol; and a process for producing the intermediate.